Clinical trials: Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe…
- Trial name
- NCT01500278
- Testing
- Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
- Where
- 175 sites in United States, Australia and 18 more
- Volunteers
- 915 people
- Sponsor
- UCB Pharma SA
Rheumatoid Arthritis
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
This prospective, observational study will evaluate the efficacy, safety and tolerability of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or…
- Trial name
- NCT01770834
- Where
- 12 sites in Kuwait, Lebanon and 2 more
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
- Trial name
- NCT05848258
- Testing
- LY3871801
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This 2 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with traditional Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy in…
- Trial name
- NCT00106574
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 146 sites in United States, Argentina and 17 more
- Volunteers
- 1,220 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is effective in treating moderate to severe rheumatoid arthritis.
- Trial name
- RA (NCT01404585)
- Testing
- BMS-817399
- Where
- 29 sites in United States, Argentina and 5 more
- Volunteers
- 123 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 1 (NCT02760368)
- Testing
- Olokizumab
- Where
- 40 sites in Belarus, Bulgaria and 1 more
- Volunteers
- 428 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis (RA)
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis
- Trial name
- NCT06596772
- Testing
- MB04 (proposed biosimilar to etanercept), Enbrel (etanercept)
- Where
- 60 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 501 people
- Sponsor
- mAbxience Research S.L.
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Rheumatoid Arthrits
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs
- Trial name
- NCT07856511
- Testing
- Proximod
- Volunteers
- 590 people
- Sponsor
- Jiankuan (Suzhou) Biotechnology Company Limited
Rheumatoid Arthritis
Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients With Rheumatoid Arthritis
The goal of this clinical trial is to evaluate the efficacy of FBL-MTX administered by subcutaneous route in Rheumatoid Arthritis patients.
- Trial name
- NCT06565273
- Testing
- FBL-MTX
- Where
- 8 sites in Portugal
- Volunteers
- 40 people
- Sponsor
- SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
Sjögren's Syndrome
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from…
- Trial name
- NCT02843659
- Testing
- BMS-931699, BMS-986142
- Where
- 34 sites in United States, Australia and 9 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.
- Trial name
- RA-BEYOND (NCT01885078)
- Testing
- Baricitinib
- Where
- 408 sites in United States, Argentina and 36 more
- Volunteers
- 2,877 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
This randomized, double-blind, parallel group study will assess the safety, disease remission, and prevention of structural joint damage in patients with early moderate to severe rheumatoid arthritis treated with tocilizumab as…
- Trial name
- NCT01007435
- Testing
- Tocilizumab, Methotrexate
- Where
- 236 sites in United States, Argentina and 34 more
- Volunteers
- 1,162 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT04171414
- Testing
- CT-P17 SC AI (adalimumab)
- Where
- Poland
- Volunteers
- 62 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA).
- Trial name
- NCT00777816
- Testing
- XOMA 052
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- XOMA (US) LLC
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
Brief Summary: This is a randomized, double-blind study comparing LNK01001 to placebo in Chinese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic…
- Trial name
- NCT06276998
- Testing
- LNK01001
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Rheumatoid Arthritis
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to assess the efficacy and safety of tocilizumab vs placebo, in combination with stable, ongoing therapy, with regard to reduction in signs and symptoms in patients with moderate to severe active RA…
- Trial name
- NCT01211834
- Testing
- tocilizumab, DMARDs
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- JW Pharmaceutical
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
- Trial name
- NCT04333771
- Testing
- SHR0302
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
This open-label study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis (RA) on background non-biologic DMARDs who have an…
- Trial name
- NCT01245439
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 17 sites in Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Primary Objective: To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid…
- Trial name
- SariPRO (NCT03449758)
- Testing
- SARILUMAB, Azathioprine, Chloroquine
- Where
- 33 sites in France
- Volunteers
- 84 people
- Sponsor
- Sanofi